@article{210df59b10194caa919204fc8370bb44,
title = "Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma",
abstract = "Background. In the current study, we pooled imaging data in newly diagnosed glioblastoma (GBM) patients from international multicenter clinical trials, single institution databases, and multicenter clinical trial con-sortiums to identify the relationship between postoperative residual enhancing tumor volume and overall survival (OS). Methods. Data from 1511 newly diagnosed GBM patients from 5 data sources were included in the current study: (i) a single institution database from UCLA (N = 398; Discovery); (ii) patients from the Ben and Cathy Ivy Foundation for Early Phase Clinical Trials Network Radiogenomics Database (N = 262 from 8 centers; Confirmation); (iii) the chemoradiation placebo arm from an international phase III trial (AVAglio; N = 394 from 120 locations in 23 countries; Validation); (iv) the experimental arm from AVAglio examining chemoradiation plus bevacizumab (N = 404 from 120 locations in 23 countries; Exploratory Set 1); and (v) an Alliance (N0874) phase I/II trial of vorinostat plus chemoradiation (N = 53; Exploratory Set 2). Postsurgical, residual enhancing disease was quantified using T1 subtraction maps. Multivariate Cox regression models were used to determine influence of clinical variables, O6-methylguanine-DNA methyltransferase (MGMT) status, and residual tumor volume on OS. Results. A log-linear relationship was observed between postoperative, residual enhancing tumor volume and OS in newly diagnosed GBM treated with standard chemoradiation. Postoperative tumor volume is a prognostic factor for OS (P < 0.01), regardless of therapy, age, and MGMT promoter methylation status. Conclusion. Postsurgical, residual contrast-enhancing disease significantly negatively influences survival in patients with newly diagnosed GBM treated with chemoradiation with or without concomitant experimental therapy.",
keywords = "Bevacizumab, Clinical trials, Contrast-enhancing tumor volume, GBM, New glioblastoma, Prognosis, T1 subtraction",
author = "Ellingson, {Benjamin M.} and Abrey, {Lauren E.} and Nelson, {Sarah J.} and Kaufmann, {Timothy J.} and Josep Garcia and Olivier Chinot and Frank Saran and Ryo Nishikawa and Roger Henriksson and Mason, {Warren P.} and Wolfgang Wick and Nicholas Butowski and Ligon, {Keith L.} and Gerstner, {Elizabeth R.} and Howard Colman and {De Groot}, John and Susan Chang and Ingo Mellinghoff and Young, {Robert J.} and Alexander, {Brian M.} and Rivka Colen and Taylor, {Jennie W.} and Isabel Arrillaga-Romany and Arnav Mehta and Huang, {Raymond Y.} and Pope, {Whitney B.} and David Reardon and Tracy Batchelor and Michael Prados and Evanthia Galanis and Wen, {Patrick Y.} and Cloughesy, {Timothy F.}",
note = "Funding Information: This work was supported by the Ben and Catherine Ivy Foundation Clinical Trials Network (B.M.E., S.J.N., N.B., T.F.C., K.L.L., E.R.G., H.C., J.d.G., S.C., I.M., J.W.T., I.A-R., D.R., M.P., P.Y.W.); National Brain Tumor Society Research Grant (B.M.E., T.F.C.); American Cancer Society (ACS) Research Scholar Grant (RSG-15-003-01-CCE) (B.M.E.); Roche/Genentech Research Grant (B.M.E., T.F.C.); Art of the Brain (T.F.C.); Ziering Family Foundation in memory of Sigi Ziering (T.F.C.); Singleton Family Foundation (T.F.C.); UCLA SPORE in Brain Cancer (NIH/NCI 1P50CA211015-01A1) (B.M.E., W.B.P., T.F.C.) Funding Information: Hoffman La-Roche, Siemens, Nativis, Medicenna, MedQIA, Bristol Meyers Squibb, Imaging Endpoints, Agios; paid consultant: Nativis, MedQIA, Siemens, Hoffman La-Roche, Imaging Endpoints, Medicenna, Agios; grant funding: Hoffman La-Roche, Siemens, Agios, Janssen. H.C.—Advisory board: Roche, Genentech, Novocure, Insys, Abbvie; grant funding: Newlink Genetics, Plexxikon, Kadmon, Orbus, merck, DNATrix. W.P.M.—Consultant: Roche, Merck, Abbvie, Celgene, Triphase. Publisher Copyright: {\textcopyright} The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.",
year = "2018",
month = aug,
day = "2",
doi = "10.1093/neuonc/noy053",
language = "English (US)",
volume = "20",
pages = "1240--1250",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "9",
}